A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-305 Following a Single Oral Dose in Healthy Male Subjects
Latest Information Update: 21 Sep 2022
At a glance
- Drugs EDP 305 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
Most Recent Events
- 28 Nov 2018 New trial record